{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:32:54Z","timestamp":1790069574826,"version":"4.0.1"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10067-019-04699-8","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T04:49:38Z","timestamp":1564634978000},"page":"2977-2994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["A comprehensive review of rituximab therapy in rheumatoid arthritis patients"],"prefix":"10.1007","volume":"38","author":[{"given":"Soheil","family":"Tavakolpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Alesaeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Darvishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"GhasemiAdl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Darabi-Monadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meisam","family":"Akhlaghdoust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Elikaei Behjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Jafarieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"issue":"10","key":"4699_CR1","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k","volume":"41","author":"AM van Gestel","year":"1998","unstructured":"van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41(10):1845\u20131850. https:\/\/doi.org\/10.1002\/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4699_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00281-017-0627-z","volume":"39","author":"VFAM Derksen","year":"2017","unstructured":"Derksen VFAM, Huizinga TWJ, van der Woude D (2017) The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol 39(4):437\u2013446. https:\/\/doi.org\/10.1007\/s00281-017-0627-z","journal-title":"Semin Immunopathol"},{"issue":"7","key":"4699_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","volume":"92","author":"CA Wijbrandts","year":"2017","unstructured":"Wijbrandts CA, Tak PP (2017) Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc 92(7):1129\u20131143. https:\/\/doi.org\/10.1016\/j.mayocp.2017.05.009","journal-title":"Mayo Clin Proc"},{"key":"4699_CR4","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"4699_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 74(2):415\u2013421. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204021","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 4","key":"4699_CR6","doi-asserted-by":"publisher","first-page":"iv77","DOI":"10.1136\/ard.2005.042507","volume":"64","author":"E Clark","year":"2005","unstructured":"Clark E, Ledbetter J (2005) How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 64(Suppl 4):iv77\u2013iv80. https:\/\/doi.org\/10.1136\/ard.2005.042507","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4699_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/art.21650","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC (2006) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54(3):723\u2013732. https:\/\/doi.org\/10.1002\/art.21650","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4699_CR8","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/art.38107","volume":"65","author":"J Melet","year":"2013","unstructured":"Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G (2013) Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 65(11):2783\u20132790. https:\/\/doi.org\/10.1002\/art.38107","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4699_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909\u2013920. https:\/\/doi.org\/10.1136\/ard.2010.144998","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4699_CR10","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72(9):1496\u20131502. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201956","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4699_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/1756-185x.12164","volume":"17","author":"D Nicholls","year":"2014","unstructured":"Nicholls D, Zochling J, Boers A, Champion G, Mathers D, Riordan J, Youssef P, Scott J, Griffiths H (2014) A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice. Int J Rheum Dis 17(7):755\u2013761. https:\/\/doi.org\/10.1111\/1756-185x.12164","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"4699_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3899\/jrheum.140853","volume":"42","author":"KJ Aaltonen","year":"2015","unstructured":"Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirila L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordstrom D (2015) Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 42(3):372\u2013378. https:\/\/doi.org\/10.3899\/jrheum.140853","journal-title":"J Rheumatol"},{"issue":"10","key":"4699_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42(10):1761\u20131766. https:\/\/doi.org\/10.3899\/jrheum.150051","journal-title":"J Rheumatol"},{"issue":"5","key":"4699_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/acr.20419","volume":"63","author":"W Rigby","year":"2011","unstructured":"Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A (2011) Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken) 63(5):711\u2013720. https:\/\/doi.org\/10.1002\/acr.20419","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"4699_CR15","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793\u20132806. https:\/\/doi.org\/10.1002\/art.22025","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4699_CR16","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54(5):1390\u20131400. https:\/\/doi.org\/10.1002\/art.21778","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4699_CR17","first-page":"2109","volume":"32","author":"J Higashida","year":"2005","unstructured":"Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM (2005) Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 32(11):2109\u20132115","journal-title":"J Rheumatol"},{"key":"4699_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874312900701010001","volume":"1","author":"LY Ho","year":"2007","unstructured":"Ho LY, Mok CC, To CH, Anselm M, Cheung MY, Yu KL (2007) Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study. Open Rheumatol J 1:1\u20134. https:\/\/doi.org\/10.2174\/1874312900701010001","journal-title":"Open Rheumatol J"},{"issue":"3","key":"4699_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.bmt.1704570","volume":"34","author":"J Moore","year":"2004","unstructured":"Moore J, Ma D, Will R, Cannell P, Handel M, Milliken S (2004) A phase II study of rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 34(3):241\u2013247. https:\/\/doi.org\/10.1038\/sj.bmt.1704570","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"4699_CR20","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/rheumatology\/kel453","volume":"46","author":"RN Jois","year":"2007","unstructured":"Jois RN, Masding A, Somerville M, Gaffney K, Scott DG (2007) Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatology (Oxford) 46(6):980\u2013982. https:\/\/doi.org\/10.1093\/rheumatology\/kel453","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4699_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/art.23715","volume":"59","author":"E Keystone","year":"2008","unstructured":"Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, Tak PP, Broder MS, Yu E, Cravets M, Magrini F, Jost F (2008) Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 59(6):785\u2013793. https:\/\/doi.org\/10.1002\/art.23715","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4699_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/acr.21663","volume":"64","author":"MM Soliman","year":"2012","unstructured":"Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM (2012) Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology biologics register. Arthritis Care Res (Hoboken) 64(8):1108\u20131115. https:\/\/doi.org\/10.1002\/acr.21663","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10041","key":"4699_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0140-6736(16)00380-9","volume":"388","author":"D Porter","year":"2016","unstructured":"Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB (2016) Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388(10041):239\u2013247. https:\/\/doi.org\/10.1016\/s0140-6736(16)00380-9","journal-title":"Lancet"},{"issue":"1","key":"4699_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.2010.137703","volume":"70","author":"PP Tak","year":"2011","unstructured":"Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70(1):39\u201346. https:\/\/doi.org\/10.1136\/ard.2010.137703","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4699_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","volume":"71","author":"PP Tak","year":"2012","unstructured":"Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T (2012) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71(3):351\u2013357. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200170","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4699_CR26","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s10067-017-3742-2","volume":"36","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM (2017) Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. Clin Rheumatol 36(9):2135\u20132140. https:\/\/doi.org\/10.1007\/s10067-017-3742-2","journal-title":"Clin Rheumatol"},{"key":"4699_CR27","doi-asserted-by":"publisher","first-page":"l67","DOI":"10.1136\/bmj.l67","volume":"364","author":"JE Gottenberg","year":"2019","unstructured":"Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X (2019) Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. Bmj 364:l67. https:\/\/doi.org\/10.1136\/bmj.l67","journal-title":"Bmj"},{"key":"4699_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/rheumatology\/kex418","volume":"57","author":"F Coutant","year":"2017","unstructured":"Coutant F, Rouzaire P, Soubrier M (2017) An unexpected response to rituximab in a patient with rheumatoid arthritis. Rheumatology (Oxford) 57:580\u2013582. https:\/\/doi.org\/10.1093\/rheumatology\/kex418","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4699_CR29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/art.22400","volume":"56","author":"K Vos","year":"2007","unstructured":"Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56(3):772\u2013778. https:\/\/doi.org\/10.1002\/art.22400","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4699_CR30","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar2798","volume":"11","author":"M Nakou","year":"2009","unstructured":"Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT (2009) Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 11(4):R131. https:\/\/doi.org\/10.1186\/ar2798","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"4699_CR31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/art.27359","volume":"62","author":"EM Vital","year":"2010","unstructured":"Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, Ponchel F, Emery P (2010) Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62(5):1273\u20131279. https:\/\/doi.org\/10.1002\/art.27359","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4699_CR32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/ard.2010.148759","volume":"70","author":"K Chatzidionysiou","year":"2011","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordstrom DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF (2011) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 70(9):1575\u20131580. https:\/\/doi.org\/10.1136\/ard.2010.148759","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4699_CR33","first-page":"991","volume":"29","author":"J Narvaez","year":"2011","unstructured":"Narvaez J, Diaz-Torne C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Diaz-Lopez C, Sanmarti R, Nolla JM (2011) Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 29(6):991\u2013997","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"4699_CR34","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.131279","volume":"41","author":"F De Keyser","year":"2014","unstructured":"De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 41(9):1761\u20131765. https:\/\/doi.org\/10.3899\/jrheum.131279","journal-title":"J Rheumatol"},{"issue":"7","key":"4699_CR35","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3899\/jrheum.141043","volume":"42","author":"LR Harrold","year":"2015","unstructured":"Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, Kremer JM, Greenberg JD (2015) Effectiveness of rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: results from the CORRONA registry. J Rheumatol 42(7):1090\u20131098. https:\/\/doi.org\/10.3899\/jrheum.141043","journal-title":"J Rheumatol"},{"issue":"12","key":"4699_CR36","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","volume":"48","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S (2009) Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 48(12):1557\u20131559. https:\/\/doi.org\/10.1093\/rheumatology\/kep314","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4699_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/rhu.0000000000000166","volume":"21","author":"H Valleala","year":"2015","unstructured":"Valleala H, Korpela M, Hienonen-Kempas T, Immonen K, Lahteenmaki J, Uusitalo T, Komulainen R, Mottonen T, Hannonen P (2015) Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs. J Clin Rheumatol 21(1):24\u201330. https:\/\/doi.org\/10.1097\/rhu.0000000000000166","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"4699_CR38","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/1756-185x.13511","volume":"22","author":"KC Wang","year":"2019","unstructured":"Wang KC, Liao HT, Chen WS, Lai CC, Chou CT, Chen MH, Tsai CY (2019) Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: a single-center experience in Taiwan. Int J Rheum Dis 22(5):860\u2013868. https:\/\/doi.org\/10.1111\/1756-185x.13511","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"4699_CR39","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1136\/ard.2010.136093","volume":"70","author":"EE Arts","year":"2011","unstructured":"Arts EE, Jansen TL, Den Broeder A, Vonkeman HE, Dutmer E, Van de Laar MA, Van Riel PL, Fransen J (2011) Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry. Ann Rheum Dis 70(5):877\u2013878. https:\/\/doi.org\/10.1136\/ard.2010.136093","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4699_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/annrheumdis-2012-202454","volume":"72","author":"S Das","year":"2013","unstructured":"Das S, Fernandez Matilla M, Dass S, Buch MH, Rawstron AC, Vital EM, Emery P (2013) Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. Ann Rheum Dis 72(3):463\u2013464. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202454","journal-title":"Ann Rheum Dis"},{"key":"4699_CR41","doi-asserted-by":"publisher","first-page":"689426","DOI":"10.1155\/2014\/689426","volume":"2014","author":"D Mazilu","year":"2014","unstructured":"Mazilu D, Gudu T, Ionescu R, Opris D (2014) Statins do not influence long-term rituximab clinical efficiency in rheumatoid arthritis patients. Biomed Res Int 2014:689426\u2013689424. https:\/\/doi.org\/10.1155\/2014\/689426","journal-title":"Biomed Res Int"},{"issue":"10","key":"4699_CR42","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/annrheumdis-2014-205474","volume":"73","author":"PB Lehane","year":"2014","unstructured":"Lehane PB, Lacey S, Hessey EW, Jahreis A (2014) Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis. Ann Rheum Dis 73(10):1906\u20131908. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205474","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4699_CR43","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69(9):1629\u20131635. https:\/\/doi.org\/10.1136\/ard.2009.119933","journal-title":"Ann Rheum Dis"},{"key":"4699_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13075-016-0951-z","volume":"18","author":"K Chatzidionysiou","year":"2016","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordstrom DC, Gabay C, Canhao H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF (2016) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther 18:50. https:\/\/doi.org\/10.1186\/s13075-016-0951-z","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"4699_CR45","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","volume":"49","author":"A Rubbert-Roth","year":"2010","unstructured":"Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, Collinson N, Shaw TM (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49(9):1683\u20131693. https:\/\/doi.org\/10.1093\/rheumatology\/keq116","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4699_CR46","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/acr.22116","volume":"66","author":"M Bredemeier","year":"2014","unstructured":"Bredemeier M, de Oliveira FK, Rocha CM (2014) Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 66(2):228\u2013235. https:\/\/doi.org\/10.1002\/acr.22116","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"4699_CR47","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s10067-015-2977-z","volume":"34","author":"M Bredemeier","year":"2015","unstructured":"Bredemeier M, Campos GG, de Oliveira FK (2015) Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol 34(10):1801\u20131805. https:\/\/doi.org\/10.1007\/s10067-015-2977-z","journal-title":"Clin Rheumatol"},{"key":"4699_CR48","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/rheumatology\/kex446","volume":"57","author":"J Henry","year":"2017","unstructured":"Henry J, Gottenberg JE, Rouanet S, Pavy S, Sellam J, Tubach F, Belkhir R, Mariette X, Seror R (2017) Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. Rheumatology (Oxford) 57:538\u2013547. https:\/\/doi.org\/10.1093\/rheumatology\/kex446","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4699_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.reuma.2015.07.003","volume":"12","author":"N Mena-Vazquez","year":"2016","unstructured":"Mena-Vazquez N, Manrique-Arija S, Urena-Garnica I, Romero-Barco CM, Jimenez-Nunez FG, Coret V, Irigoyen-Oyarzabal MV, Fernandez-Nebro A (2016) Eficiency of different doses of rituximab in rheumatoid arthritis. Reumatol Clin 12(3):139\u2013145. https:\/\/doi.org\/10.1016\/j.reuma.2015.07.003","journal-title":"Reumatol Clin"},{"issue":"8","key":"4699_CR50","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1136\/annrheumdis-2013-203480","volume":"73","author":"X Mariette","year":"2014","unstructured":"Mariette X, Rouanet S, Sibilia J, Combe B, Le Loet X, Tebib J, Jourdan R, Dougados M (2014) Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 73(8):1508\u20131514. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203480","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4699_CR51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3899\/jrheum.160460","volume":"44","author":"K Chatzidionysiou","year":"2017","unstructured":"Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordstrom D, Canhao H, Santos MJ, Tomsic M, Rotar Z, Hernandez MV, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven R (2017) Rituximab retreatment in rheumatoid arthritis in a real-life cohort: data from the CERERRA collaboration. J Rheumatol 44(2):162\u2013169. https:\/\/doi.org\/10.3899\/jrheum.160460","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"4699_CR52","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/annrheumdis-2019-eular.6215","volume":"78","author":"L Schapink","year":"2019","unstructured":"Schapink L, Nd B, Ad B, Verhoef L (2019) AB0408 fixed-interval versus on-demand retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study. Ann Rheum Dis 78(Suppl 2):1664\u20131665. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.6215","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4699_CR53","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","volume":"74","author":"EM Vital","year":"2015","unstructured":"Vital EM, Dass S, Buch MH, Rawstron AC, Emery P (2015) An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis 74(6):1195\u20131201. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204544","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4699_CR54","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896\u20133908. https:\/\/doi.org\/10.1002\/art.23059","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4699_CR55","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3899\/jrheum.091127","volume":"37","author":"H Bastian","year":"2010","unstructured":"Bastian H, Zinke S, Egerer K, Breuer S, Safari F, Burmester GR, Feist E (2010) Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study. J Rheumatol 37(5):1069\u20131071. https:\/\/doi.org\/10.3899\/jrheum.091127","journal-title":"J Rheumatol"},{"key":"4699_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1471-2474-15-177","volume":"15","author":"CH Pritchard","year":"2014","unstructured":"Pritchard CH, Greenwald MW, Kremer JM, Gaylis NB, Rigby W, Zlotnick S, Chung C, Jaber B, Reiss W (2014) Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskelet Disord 15:177. https:\/\/doi.org\/10.1186\/1471-2474-15-177","journal-title":"BMC Musculoskelet Disord"},{"key":"4699_CR57","doi-asserted-by":"publisher","unstructured":"Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE (2018) Long-term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.23781","DOI":"10.1002\/acr.23781"},{"issue":"3","key":"4699_CR58","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","volume":"78","author":"KL Gron","year":"2019","unstructured":"Gron KL, Arkema EV, Glintborg B, Mehnert F, Ostergaard M, Dreyer L, Norgaard M, Krogh NS, Askling J, Hetland ML (2019) Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis 78(3):320\u2013327. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214326","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4699_CR59","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"JE Gottenberg","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loet X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62(9):2625\u20132632. https:\/\/doi.org\/10.1002\/art.27555","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4699_CR60","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.amjmed.2017.01.014","volume":"130","author":"C Goates","year":"2017","unstructured":"Goates C, Tsuha S, Working S, Carey J, Spivak ES (2017) Seronegative West Nile virus infection in a patient treated with rituximab for rheumatoid arthritis. Am J Med 130(6):e257\u2013e258. https:\/\/doi.org\/10.1016\/j.amjmed.2017.01.014","journal-title":"Am J Med"},{"issue":"2","key":"4699_CR61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.diagmicrobio.2016.02.016","volume":"85","author":"J Raffalli","year":"2016","unstructured":"Raffalli J, Wormser GP (2016) Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis. Diagn Microbiol Infect Dis 85(2):231\u2013232. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.02.016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"4699_CR62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jbspin.2011.07.003","volume":"79","author":"E Ghrenassia","year":"2012","unstructured":"Ghrenassia E, Mekinian A, Rouaghe S, Ganne N, Fain O (2012) Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine 79(1):100\u2013101. https:\/\/doi.org\/10.1016\/j.jbspin.2011.07.003","journal-title":"Joint Bone Spine"},{"issue":"1","key":"4699_CR63","first-page":"91","volume":"17","author":"E Gigi","year":"2013","unstructured":"Gigi E, Georgiou T, Mougiou D, Boura P, Raptopoulou-Gigi M (2013) Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia 17(1):91\u201393","journal-title":"Hippokratia"},{"issue":"3","key":"4699_CR64","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.reuma.2013.05.011","volume":"10","author":"TC Salman-Monte","year":"2014","unstructured":"Salman-Monte TC, Lisbona MP, Garcia-Retortillo M, Maymo J (2014) Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin 10(3):196\u2013197. https:\/\/doi.org\/10.1016\/j.reuma.2013.05.011","journal-title":"Reumatol Clin"},{"issue":"5","key":"4699_CR65","first-page":"831","volume":"35","author":"YC Tien","year":"2017","unstructured":"Tien YC, Yen HH, Chiu YM (2017) Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol 35(5):831\u2013836","journal-title":"Clin Exp Rheumatol"},{"key":"4699_CR66","doi-asserted-by":"publisher","unstructured":"Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY (2019) Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation. Int J Rheum Dis. https:\/\/doi.org\/10.1111\/1756-185x.13582","DOI":"10.1111\/1756-185x.13582"},{"issue":"1","key":"4699_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jmii.2011.12.020","volume":"46","author":"KM Lin","year":"2013","unstructured":"Lin KM, Lin JC, Tseng WY, Cheng TT (2013) Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J Microbiol Immunol Infect 46(1):65\u201367. https:\/\/doi.org\/10.1016\/j.jmii.2011.12.020","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"4699_CR68","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2014-206711","volume":"74","author":"YM Chen","year":"2015","unstructured":"Chen YM, Chen HH, Chen YH, Hsieh TY, Hsieh CW, Hung WT, Lan JL, Chen DY (2015) A comparison of safety profiles of tumour necrosis factor alpha inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis 74(3):626\u2013627. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206711","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4699_CR69","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/ar3047","volume":"12","author":"M Rehnberg","year":"2010","unstructured":"Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI (2010) Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 12(3):R111. https:\/\/doi.org\/10.1186\/ar3047","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4699_CR70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S van Assen","year":"2010","unstructured":"van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62(1):75\u201381. https:\/\/doi.org\/10.1002\/art.25033","journal-title":"Arthritis Rheum"},{"key":"4699_CR71","doi-asserted-by":"publisher","unstructured":"Intongkam S, Samakarnthai P, Pakchotanon R, Narongroeknawin P, Assavatanabodee P, Chaiamnuay S (2018) Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying Antirheumatic drugs and\/or biologics therapy. J Clin Rheumatol:1. https:\/\/doi.org\/10.1097\/rhu.0000000000000877","DOI":"10.1097\/rhu.0000000000000877"},{"issue":"8","key":"4699_CR72","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1002\/art.22811","volume":"56","author":"S Dass","year":"2007","unstructured":"Dass S, Vital EM, Emery P (2007) Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 56(8):2715\u20132718. https:\/\/doi.org\/10.1002\/art.22811","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4699_CR73","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3899\/jrheum.111256","volume":"39","author":"SA Hardcastle","year":"2012","unstructured":"Hardcastle SA, Gibbs S, Williamson L (2012) Atypical psoriasis following rituximab for rheumatoid arthritis. J Rheumatol 39(6):1303\u20131304. https:\/\/doi.org\/10.3899\/jrheum.111256","journal-title":"J Rheumatol"},{"issue":"11","key":"4699_CR74","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1007\/s00296-012-2581-3","volume":"33","author":"GM Guidelli","year":"2013","unstructured":"Guidelli GM, Fioravanti A, Rubegni P, Feci L (2013) Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Rheumatol Int 33(11):2927\u20132930. https:\/\/doi.org\/10.1007\/s00296-012-2581-3","journal-title":"Rheumatol Int"},{"issue":"5","key":"4699_CR75","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jbspin.2013.02.001","volume":"80","author":"G Ozen","year":"2013","unstructured":"Ozen G, Ergun T, Oner SY, Demirkesen C, Inanc N (2013) Widespread psoriasis induced by rituximab in a patient with rheumatoid arthritis: an unexpected adverse reaction. Joint Bone Spine 80(5):545\u2013547. https:\/\/doi.org\/10.1016\/j.jbspin.2013.02.001","journal-title":"Joint Bone Spine"},{"issue":"4","key":"4699_CR76","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.jaad.2011.12.010","volume":"67","author":"AM Brunasso","year":"2012","unstructured":"Brunasso AM, Massone C (2012) Plantar pustulosis during rituximab therapy for rheumatoid arthritis. J Am Acad Dermatol 67(4):e148\u2013e150. https:\/\/doi.org\/10.1016\/j.jaad.2011.12.010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4699_CR77","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.1002\/ibd.22963","volume":"19","author":"M Bhalme","year":"2013","unstructured":"Bhalme M, Hayes S, Norton A, Lal S, Chinoy H, Paine P (2013) Rituximab-associated colitis. Inflamm Bowel Dis 19(3):E41\u2013E43. https:\/\/doi.org\/10.1002\/ibd.22963","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"4699_CR78","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"RF van Vollenhoven","year":"2010","unstructured":"van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3):558\u2013567. https:\/\/doi.org\/10.3899\/jrheum.090856","journal-title":"J Rheumatol"},{"issue":"12","key":"4699_CR79","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/acr.22912","volume":"68","author":"LR Harrold","year":"2016","unstructured":"Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD (2016) Risk of infection associated with subsequent biologic agent use after rituximab: results from a National Rheumatoid Arthritis Patient registry. Arthritis Care Res (Hoboken) 68(12):1888\u20131893. https:\/\/doi.org\/10.1002\/acr.22912","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4699_CR80","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/rheumatology\/kex304","volume":"57","author":"L Silva-Fernandez","year":"2017","unstructured":"Silva-Fernandez L, De Cock D, Lunt M, Low AS, Watson KD, Symmons DPM, Hyrich KL (2017) Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Rheumatology (Oxford) 57:1533\u20131540. https:\/\/doi.org\/10.1093\/rheumatology\/kex304","journal-title":"Rheumatology (Oxford)"},{"key":"4699_CR81","doi-asserted-by":"publisher","unstructured":"Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y (2019) Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. https:\/\/doi.org\/10.1111\/1756-185x.13596","DOI":"10.1111\/1756-185x.13596"},{"issue":"6","key":"4699_CR82","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/annrheumdis-2011-200719","volume":"71","author":"A Meyer","year":"2012","unstructured":"Meyer A, Theulin A, Chatelus E, Argemi X, Sordet C, Javier RM, Hansmann Y, Sibilia J, Gottenberg JE (2012) Campylobacter fetus infection in three rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis 71(6):1094\u20131095. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200719","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4699_CR83","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jbspin.2012.10.018","volume":"80","author":"S Ottaviani","year":"2013","unstructured":"Ottaviani S, Tiendrebeogo J, Choudat L, Gill G, Palazzo E, Meyer O, Dieude P (2013) Knee tuberculosis under rituximab therapy for rheumatoid arthritis. Joint Bone Spine 80(4):435\u2013436. https:\/\/doi.org\/10.1016\/j.jbspin.2012.10.018","journal-title":"Joint Bone Spine"},{"issue":"2","key":"4699_CR84","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jbspin.2012.07.011","volume":"80","author":"A Rouil","year":"2013","unstructured":"Rouil A, Pollet S, Martin A, Tattevin P, Perdriger A (2013) Severe Pasteurella multocida infection in a patient on rituximab therapy for rheumatoid arthritis. Joint Bone Spine 80(2):224\u2013225. https:\/\/doi.org\/10.1016\/j.jbspin.2012.07.011","journal-title":"Joint Bone Spine"},{"key":"4699_CR85","doi-asserted-by":"publisher","unstructured":"Santos VA, Tobon GJ, Canas CA (2018) Development of bronchiectasis during long-term rituximab treatment for rheumatoid arthritis. Adv Respir Med. https:\/\/doi.org\/10.5603\/ARM.a2018.0050","DOI":"10.5603\/ARM.a2018.0050"},{"issue":"9","key":"4699_CR86","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68(9):1156\u20131164. https:\/\/doi.org\/10.1001\/archneurol.2011.103","journal-title":"Arch Neurol"},{"issue":"5","key":"4699_CR87","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3899\/jrheum.130526","volume":"41","author":"R Abdulkader","year":"2014","unstructured":"Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA (2014) Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol 41(5):858\u2013861. https:\/\/doi.org\/10.3899\/jrheum.130526","journal-title":"J Rheumatol"},{"issue":"3","key":"4699_CR88","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00296-009-1202-2","volume":"31","author":"A Pyrpasopoulou","year":"2011","unstructured":"Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S (2011) Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 31(3):403\u2013404. https:\/\/doi.org\/10.1007\/s00296-009-1202-2","journal-title":"Rheumatol Int"},{"issue":"5","key":"4699_CR89","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3899\/jrheum.151105","volume":"43","author":"V Varisco","year":"2016","unstructured":"Varisco V, Vigano M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, Sarzi-Puttini P (2016) Low risk of hepatitis B virus reactivation in HBsAg-negative\/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study. J Rheumatol 43(5):869\u2013874. https:\/\/doi.org\/10.3899\/jrheum.151105","journal-title":"J Rheumatol"},{"issue":"6","key":"4699_CR90","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jbspin.2017.03.002","volume":"84","author":"G Clavel","year":"2017","unstructured":"Clavel G, Moulignier A, Semerano L (2017) Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Joint Bone Spine 84(6):671\u2013675. https:\/\/doi.org\/10.1016\/j.jbspin.2017.03.002","journal-title":"Joint Bone Spine"},{"issue":"5","key":"4699_CR91","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/rheumatology\/ken113","volume":"47","author":"ML Burr","year":"2008","unstructured":"Burr ML, Malaviya AP, Gaston JH, Carmichael AJ, Ostor AJ (2008) Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford) 47(5):738\u2013739. https:\/\/doi.org\/10.1093\/rheumatology\/ken113","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4699_CR92","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/rheumatology\/ken143","volume":"47","author":"N Jung","year":"2008","unstructured":"Jung N, Owczarczyk K, Hellmann M, Lehmann C, Fatkenheuer G, Hallek M, Rubbert A (2008) Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology (Oxford) 47(6):932\u2013933. https:\/\/doi.org\/10.1093\/rheumatology\/ken143","journal-title":"Rheumatology (Oxford)"},{"key":"4699_CR93","doi-asserted-by":"publisher","first-page":"bcr2012006585","DOI":"10.1136\/bcr-2012-006585","volume":"2013","author":"Y Pehlivan","year":"2013","unstructured":"Pehlivan Y, Kisacik B, Bosnak VK, Onat AM (2013) Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis. BMJ Case Rep 2013:bcr2012006585. https:\/\/doi.org\/10.1136\/bcr-2012-006585","journal-title":"BMJ Case Rep"},{"issue":"10","key":"4699_CR94","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/rheumatology\/keq159","volume":"49","author":"M Magnusson","year":"2010","unstructured":"Magnusson M, Brisslert M, Zendjanchi K, Lindh M, Bokarewa MI (2010) Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford) 49(10):1911\u20131919. https:\/\/doi.org\/10.1093\/rheumatology\/keq159","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"4699_CR95","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1136\/ard.2007.071878","volume":"66","author":"LB Gelinck","year":"2007","unstructured":"Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM (2007) Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66(10):1402\u20131403. https:\/\/doi.org\/10.1136\/ard.2007.071878","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4699_CR96","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3899\/jrheum.111347","volume":"39","author":"L Thomas","year":"2012","unstructured":"Thomas L, Canoui-Poitrine F, Gottenberg JE, Economu-Dubosc A, Medkour F, Chevalier X, Bastuji-Garin S, Le Louet H, Farrenq V, Claudepierre P (2012) Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol 39(5):893\u2013898. https:\/\/doi.org\/10.3899\/jrheum.111347","journal-title":"J Rheumatol"},{"issue":"5 suppl 1","key":"4699_CR97","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1590\/abd1806-4841.20164456","volume":"91","author":"JB Vasconcellos","year":"2016","unstructured":"Vasconcellos JB, Pereira DD, Vargas TJ, Levy RA, Pinheiro GD, Cursi IB (2016) Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. An Bras Dermatol 91(5 suppl 1):137\u2013139. https:\/\/doi.org\/10.1590\/abd1806-4841.20164456","journal-title":"An Bras Dermatol"},{"key":"4699_CR98","doi-asserted-by":"publisher","unstructured":"Fui A, Bergantini L, Selvi E, Mazzei MA, Bennett D, Pieroni MG, Rottoli P, Bargagli E (2019) Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J. https:\/\/doi.org\/10.1111\/imj.14306","DOI":"10.1111\/imj.14306"},{"issue":"8","key":"4699_CR99","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","volume":"56","author":"MY Md Yusof","year":"2017","unstructured":"Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, Dass S, Emery P (2017) Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single Centre. Rheumatology (Oxford) 56(8):1348\u20131357. https:\/\/doi.org\/10.1093\/rheumatology\/kex072","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"4699_CR100","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/1744666x.2019.1562905","volume":"15","author":"F Paul","year":"2019","unstructured":"Paul F, Cartron G (2019) Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol 15(4):383\u2013389. https:\/\/doi.org\/10.1080\/1744666x.2019.1562905","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"4699_CR101","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/rheumatology\/kex403","volume":"57","author":"JH Salmon","year":"2018","unstructured":"Salmon JH, Perotin JM, Morel J, Drame M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE (2018) Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford) 57(1):134\u2013139. https:\/\/doi.org\/10.1093\/rheumatology\/kex403","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"4699_CR102","doi-asserted-by":"publisher","first-page":"e0201527","DOI":"10.1371\/journal.pone.0201527","volume":"13","author":"G Wheater","year":"2018","unstructured":"Wheater G, Elshahaly M, Naraghi K, Tuck SP, Datta HK, van Laar JM (2018) Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study. PLoS One 13(8):e0201527. https:\/\/doi.org\/10.1371\/journal.pone.0201527","journal-title":"PLoS One"},{"key":"4699_CR103","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60\u201365. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.009","journal-title":"J Autoimmun"},{"issue":"5","key":"4699_CR104","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.autrev.2019.03.010","volume":"18","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, Harper L, Kazmi M, Kiani-Alikhan S, Li C, Misbah S, Oni L, Price-Kuehne F, Salama A, Workman S, Wrench D, Karim MY (2019) Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review. Autoimmun Rev 18(5):535\u2013541. https:\/\/doi.org\/10.1016\/j.autrev.2019.03.010","journal-title":"Autoimmun Rev"},{"key":"4699_CR105","doi-asserted-by":"publisher","unstructured":"Lee S, Kim W, Seo W (2017) Safe use of rituximab in an elderly patient with rheumatoid arthritis and severe heart failure: a case report. J Clin Rheumatol:1. https:\/\/doi.org\/10.1097\/rhu.0000000000000648","DOI":"10.1097\/rhu.0000000000000648"},{"issue":"8","key":"4699_CR106","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/rheumatology\/kes406","volume":"52","author":"J Sautner","year":"2013","unstructured":"Sautner J, Rintelen B, Leeb BF (2013) Rituximab as effective treatment in a case of severe subcutaneous nodulosis in rheumatoid arthritis. Rheumatology (Oxford) 52(8):1535\u20131537. https:\/\/doi.org\/10.1093\/rheumatology\/kes406","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"4699_CR107","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/acr.22056","volume":"65","author":"S Godot","year":"2013","unstructured":"Godot S, Gottenberg JE, Paternotte S, Pane I, Combe B, Sibilia J, Flipo RM, Schaeverbeke T, Ravaud P, Toussirot E, Berenbaum F, Mariette X, Wendling D, Sellam J (2013) Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 65(11):1874\u20131879. https:\/\/doi.org\/10.1002\/acr.22056","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"4699_CR108","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jbspin.2010.11.012","volume":"78","author":"S Slimani","year":"2011","unstructured":"Slimani S, Lukas C, Combe B, Morel J (2011) Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 78(5):484\u2013487. https:\/\/doi.org\/10.1016\/j.jbspin.2010.11.012","journal-title":"Joint Bone Spine"},{"issue":"11","key":"4699_CR109","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","volume":"55","author":"L Silva-Fernandez","year":"2016","unstructured":"Silva-Fernandez L, Lunt M, Kearsley-Fleet L, Watson KD, Dixon WG, Symmons DP, Hyrich KL (2016) The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-rheumatoid arthritis. Rheumatology (Oxford) 55(11):2033\u20132039. https:\/\/doi.org\/10.1093\/rheumatology\/kew314","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4699_CR110","doi-asserted-by":"publisher","first-page":"121","DOI":"10.17305\/bjbms.2010.2706","volume":"10","author":"S Sokolovic","year":"2010","unstructured":"Sokolovic S, Kasumagic S, Mackic-Durovic M, Aganovic-Musinovic I (2010) The impact of rituximab therapy on the chromosomes of patients with rheumatoid arthritis. Bosn J Basic Med Sci 10(2):121\u2013124. https:\/\/doi.org\/10.17305\/bjbms.2010.2706","journal-title":"Bosn J Basic Med Sci"},{"issue":"10","key":"4699_CR111","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1007\/s00296-011-2137-y","volume":"32","author":"JC Diaz","year":"2012","unstructured":"Diaz JC, Vallejo S, Canas CA (2012) Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol Int 32(10):3315\u20133317. https:\/\/doi.org\/10.1007\/s00296-011-2137-y","journal-title":"Rheumatol Int"},{"issue":"6","key":"4699_CR112","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","volume":"57","author":"AGS Oldroyd","year":"2018","unstructured":"Oldroyd AGS, Symmons DPM, Sergeant JC, Kearsley-Fleet L, Watson K, Lunt M, Hyrich KL (2018) Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford) 57(6):1089\u20131096. https:\/\/doi.org\/10.1093\/rheumatology\/key036","journal-title":"Rheumatology (Oxford)"},{"key":"4699_CR113","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.imlet.2017.08.002","volume":"190","author":"S Tavakolpour","year":"2017","unstructured":"Tavakolpour S (2017) Towards personalized medicine for patients with autoimmune diseases: opportunities and challenges. Immunol Lett 190:130\u2013138. https:\/\/doi.org\/10.1016\/j.imlet.2017.08.002","journal-title":"Immunol Lett"},{"issue":"4","key":"4699_CR114","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5114\/reum.2016.62472","volume":"54","author":"A K\u0142ak","year":"2016","unstructured":"K\u0142ak A, Paradowska-Gorycka A, Kwiatkowska B, Raciborski F (2016) Personalized medicine in rheumatology. Reumatologia 54(4):177\u2013186. https:\/\/doi.org\/10.5114\/reum.2016.62472","journal-title":"Reumatologia"},{"issue":"3","key":"4699_CR115","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/cge.13186","volume":"93","author":"S Tavakolpour","year":"2018","unstructured":"Tavakolpour S, Darvishi M, Ghasemiadl M (2018) Pharmacogenetics: a strategy for personalized medicine for autoimmune diseases. Clin Genet 93(3):481\u2013497. https:\/\/doi.org\/10.1111\/cge.13186","journal-title":"Clin Genet"},{"key":"4699_CR116","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-016-1091-1","volume":"18","author":"MH Stradner","year":"2016","unstructured":"Stradner MH, Dejaco C, Brickmann K, Graninger WB, Brezinschek HP (2016) A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. Arthritis Res Ther 18:190. https:\/\/doi.org\/10.1186\/s13075-016-1091-1","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"4699_CR117","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00296-015-3295-0","volume":"35","author":"S Piantoni","year":"2015","unstructured":"Piantoni S, Scarsi M, Tincani A, Airo P (2015) Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. Rheumatol Int 35(9):1571\u20131573. https:\/\/doi.org\/10.1007\/s00296-015-3295-0","journal-title":"Rheumatol Int"},{"issue":"2","key":"4699_CR118","doi-asserted-by":"crossref","first-page":"92","DOI":"10.59566\/IJBS.2009.5092","volume":"5","author":"A Lurati","year":"2009","unstructured":"Lurati A, Marrazza MG, Re KA, Scarpellini M (2009) Relationship between NK cell activation and clinical response in rheumatoid arthritis treated with rituximab. Int J Biomed Sci 5(2):92\u201395","journal-title":"Int J Biomed Sci"},{"key":"4699_CR119","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/btt.s29079","volume":"6","author":"A Lurati","year":"2012","unstructured":"Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M (2012) NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab. Biologics 6:83\u201387. https:\/\/doi.org\/10.2147\/btt.s29079","journal-title":"Biologics"},{"issue":"3","key":"4699_CR120","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.clim.2009.11.007","volume":"134","author":"V Parietti","year":"2010","unstructured":"Parietti V, Chifflot H, Sibilia J, Muller S, Monneaux F (2010) Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis. Clin Immunol 134(3):331\u2013339. https:\/\/doi.org\/10.1016\/j.clim.2009.11.007","journal-title":"Clin Immunol"},{"issue":"4","key":"4699_CR121","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X (2011) B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 63(4):933\u2013938. https:\/\/doi.org\/10.1002\/art.30233","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4699_CR122","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13075-016-1190-z","volume":"18","author":"J Sellam","year":"2016","unstructured":"Sellam J, Riviere E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraciolli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X (2016) Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther 18(1):294. https:\/\/doi.org\/10.1186\/s13075-016-1190-z","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"4699_CR123","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/acr.21865","volume":"65","author":"M Couderc","year":"2013","unstructured":"Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M (2013) Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken) 65(4):648\u2013652. https:\/\/doi.org\/10.1002\/acr.21865","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"4699_CR124","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2165\/11530570-000000000-00000","volume":"14","author":"A Pyrpasopoulou","year":"2010","unstructured":"Pyrpasopoulou A, Douma S, Triantafyllou A, Simoulidou E, Samara M, Parapanisiou E, Aslanidis S (2010) Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther 14(1):43\u201348. https:\/\/doi.org\/10.2165\/11530570-000000000-00000","journal-title":"Mol Diagn Ther"},{"issue":"9","key":"4699_CR125","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/annrheumdis-2012-201758","volume":"71","author":"A Khan","year":"2012","unstructured":"Khan A, Scott DL, Batley M (2012) Smoking, rheumatoid factor status and responses to rituximab. Ann Rheum Dis 71(9):1587\u20131588. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201758","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4699_CR126","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jbspin.2014.06.001","volume":"81","author":"A Gardette","year":"2014","unstructured":"Gardette A, Ottaviani S, Tubach F, Roy C, Nicaise-Roland P, Palazzo E, Gill G, Meyer O, Dieude P (2014) High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine 81(5):416\u2013420. https:\/\/doi.org\/10.1016\/j.jbspin.2014.06.001","journal-title":"Joint Bone Spine"},{"issue":"4","key":"4699_CR127","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/jcph.1341","volume":"59","author":"A Jimenez Morales","year":"2019","unstructured":"Jimenez Morales A, Maldonado-Montoro M, Martinez de la Plata JE, Perez Ramirez C, Daddaoua A, Alarcon Payer C, Exposito Ruiz M, Garcia Collado C (2019) FCGR2A\/FCGR3A gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis. J Clin Pharmacol 59(4):517\u2013531. https:\/\/doi.org\/10.1002\/jcph.1341","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4699_CR128","first-page":"253","volume":"62","author":"M Fabris","year":"2010","unstructured":"Fabris M, Quartuccio L, Lombardi S, Benucci M, Manfredi M, Saracco M, Atzeni F, Morassi P, Cimmino MA, Pontarini E, Fabro C, Pellerito R, Sarzi-Puttini P, Cutolo M, Carletto A, Bambara LM, Fischetti F, Curcio F, Tonutti E, De Vita S (2010) Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Reumatismo 62(4):253\u2013258","journal-title":"Reumatismo"},{"issue":"5","key":"4699_CR129","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jbspin.2011.10.007","volume":"79","author":"CI Daien","year":"2012","unstructured":"Daien CI, Fabre S, Rittore C, Soler S, Daien V, Tejedor G, Cadart D, Molinari N, Daures JP, Jorgensen C, Touitou I (2012) TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine 79(5):471\u2013475. https:\/\/doi.org\/10.1016\/j.jbspin.2011.10.007","journal-title":"Joint Bone Spine"},{"issue":"4","key":"4699_CR130","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/kes344","volume":"52","author":"A Ruyssen-Witrand","year":"2013","unstructured":"Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loet X, Sibilia J, Tebib J, Mariette X, Constantin A (2013) Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford) 52(4):636\u2013641. https:\/\/doi.org\/10.1093\/rheumatology\/kes344","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4699_CR131","doi-asserted-by":"publisher","first-page":"e000448","DOI":"10.1136\/rmdopen-2017-000448","volume":"3","author":"PA Juge","year":"2017","unstructured":"Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, Le Loet X, Dieude P (2017) Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open 3(2):e000448. https:\/\/doi.org\/10.1136\/rmdopen-2017-000448","journal-title":"RMD Open"},{"issue":"6","key":"4699_CR132","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/annrheumdis-2011-200337","volume":"71","author":"A Ruyssen-Witrand","year":"2012","unstructured":"Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loet X, Sibilia J, Tebib J, Mariette X, Constantin A (2012) Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 71(6):875\u2013877. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200337","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4699_CR133","first-page":"189","volume":"31","author":"K Sarsour","year":"2013","unstructured":"Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G (2013) The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-alpha antagonist therapies. Clin Exp Rheumatol 31(2):189\u2013194","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"4699_CR134","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/annrheumdis-2012-202435","volume":"73","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S (2014) The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 73(4):716\u2013721. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202435","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4699_CR135","doi-asserted-by":"publisher","first-page":"e000485","DOI":"10.1136\/rmdopen-2017-000485","volume":"3","author":"I Pal","year":"2017","unstructured":"Pal I, Szamosi S, Hodosi K, Szekanecz Z, Varoczy L (2017) Effect of Fcgamma-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis. RMD Open 3(2):e000485. https:\/\/doi.org\/10.1136\/rmdopen-2017-000485","journal-title":"RMD Open"},{"issue":"2","key":"4699_CR136","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3819","volume":"14","author":"HG Raterman","year":"2012","unstructured":"Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE (2012) The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 14(2):R95. https:\/\/doi.org\/10.1186\/ar3819","journal-title":"Arthritis Res Ther"},{"key":"4699_CR137","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jbspin.2017.02.015","volume":"85","author":"TD de Jong","year":"2017","unstructured":"de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang ASM, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X (2017) A multi-parameter response prediction model for rituximab in rheumatoid arthritis. Joint Bone Spine 85:219\u2013226. https:\/\/doi.org\/10.1016\/j.jbspin.2017.02.015","journal-title":"Joint Bone Spine"},{"issue":"10","key":"4699_CR138","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2217\/pgs.09.99","volume":"10","author":"A Julia","year":"2009","unstructured":"Julia A, Barcelo M, Erra A, Palacio C, Marsal S (2009) Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells. Pharmacogenomics 10(10):1697\u20131708. https:\/\/doi.org\/10.2217\/pgs.09.99","journal-title":"Pharmacogenomics"},{"key":"4699_CR139","doi-asserted-by":"publisher","first-page":"342524","DOI":"10.1155\/2014\/342524","volume":"2014","author":"I Duroux-Richard","year":"2014","unstructured":"Duroux-Richard I, Pers YM, Fabre S, Ammari M, Baeten D, Cartron G, Touitou I, Jorgensen C, Apparailly F (2014) Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediat Inflamm 2014:342524\u2013342529. https:\/\/doi.org\/10.1155\/2014\/342524","journal-title":"Mediat Inflamm"},{"key":"4699_CR140","doi-asserted-by":"publisher","first-page":"4963950","DOI":"10.1155\/2016\/4963950","volume":"2016","author":"EV Tchetina","year":"2016","unstructured":"Tchetina EV, Pivanova AN, Markova GA, Lukina GV, Aleksandrova EN, Aleksankin AP, Makarov SA, Kuzin AN (2016) Rituximab downregulates gene expression associated with cell proliferation, survival, and proteolysis in the peripheral blood from rheumatoid arthritis patients: a link between high baseline autophagy-related ULK1 expression and improved pain control. Arthritis 2016:4963950\u20134963912. https:\/\/doi.org\/10.1155\/2016\/4963950","journal-title":"Arthritis"},{"issue":"8","key":"4699_CR141","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s10067-015-2992-0","volume":"34","author":"H Valleala","year":"2015","unstructured":"Valleala H, Kauppi MJ, Kouri VP, Korpela M (2015) Epstein-Barr virus in peripheral blood is associated with response to rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol 34(8):1485\u20131488. https:\/\/doi.org\/10.1007\/s10067-015-2992-0","journal-title":"Clin Rheumatol"},{"issue":"1","key":"4699_CR142","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/03009742.2018.1466363","volume":"48","author":"K Chatzidionysiou","year":"2019","unstructured":"Chatzidionysiou K, Lukina G, Gabay C, Hetland ML, Hauge EM, Pavelka K, Nordstrom D, Canhao H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, Saevarsdottir S (2019) Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. Scand J Rheumatol 48(1):17\u201323. https:\/\/doi.org\/10.1080\/03009742.2018.1466363","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"4699_CR143","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/art.23902","volume":"58","author":"S Dass","year":"2008","unstructured":"Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P (2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58(10):2993\u20132999. https:\/\/doi.org\/10.1002\/art.23902","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4699_CR144","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1177\/0091270007305297","volume":"47","author":"F Breedveld","year":"2007","unstructured":"Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE (2007) Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 47(9):1119\u20131128. https:\/\/doi.org\/10.1177\/0091270007305297","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"4699_CR145","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","volume":"58","author":"TH Ramwadhdoebe","year":"2019","unstructured":"Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM, Tak PP (2019) Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford) 58(6):1075\u20131085. https:\/\/doi.org\/10.1093\/rheumatology\/key428","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"4699_CR146","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bcp.13270","volume":"83","author":"B Lioger","year":"2017","unstructured":"Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Melet J, Paintaud G, Ternant D (2017) Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. Br J Clin Pharmacol 83(8):1773\u20131781. https:\/\/doi.org\/10.1111\/bcp.13270","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"4699_CR147","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.38671","volume":"66","author":"J Sellam","year":"2014","unstructured":"Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon HJ, Rouanet S, Taoufik Y, Hendel-Chavez H, Sibilia J, Tebib J, Le Loet X, Combe B, Dougados M, Mariette X, Chiocchia G (2014) Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol 66(8):2015\u20132025. https:\/\/doi.org\/10.1002\/art.38671","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"4699_CR148","first-page":"887","volume":"33","author":"HP Tony","year":"2015","unstructured":"Tony HP, Roll P, Mei HE, Blumner E, Straka A, Gnuegge L, Dorner T (2015) Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 33(6):887\u2013894","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"4699_CR149","doi-asserted-by":"publisher","first-page":"R161","DOI":"10.1186\/ar3901","volume":"14","author":"HP Brezinschek","year":"2012","unstructured":"Brezinschek HP, Rainer F, Brickmann K, Graninger WB (2012) B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther 14(4):R161. https:\/\/doi.org\/10.1186\/ar3901","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"4699_CR150","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13317-010-0013-5","volume":"1","author":"M Fabris","year":"2010","unstructured":"Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, Fabro C, Quartuccio L, Mazzolini S, Curcio F, Tonutti E (2010) Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights 1(2):87\u201394. https:\/\/doi.org\/10.1007\/s13317-010-0013-5","journal-title":"Auto Immun Highlights"},{"issue":"1","key":"4699_CR151","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-018-1750-5","volume":"20","author":"NMT Roodenrijs","year":"2018","unstructured":"Roodenrijs NMT, de Hair MJH, Wheater G, Elshahaly M, Tekstra J, Teng YKO, Lafeber F, Hwang CC, Liu X, Sasso EH, van Laar JM (2018) The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. Arthritis Res Ther 20(1):256. https:\/\/doi.org\/10.1186\/s13075-018-1750-5","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"4699_CR152","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1002\/art.30599","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loet X, Combe B, Dougados M, Mariette X, Taoufik Y (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 63(12):3692\u20133701. https:\/\/doi.org\/10.1002\/art.30599","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4699_CR153","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jbspin.2013.04.017","volume":"81","author":"RB M'Barek","year":"2014","unstructured":"M'Barek RB, Dupre T, Tubach F, Dieude P, Palazzo E, Hayem G, Dawidowicz K, Ottaviani S, Alfaiate T, Lecon-Malais V, Boutten A, Meyer O (2014) 25-hydroxyvitamin D status does not affect the clinical rituximab response in rheumatoid arthritis. Joint Bone Spine 81(1):96\u201397. https:\/\/doi.org\/10.1016\/j.jbspin.2013.04.017","journal-title":"Joint Bone Spine"},{"issue":"1","key":"4699_CR154","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13075-018-1628-6","volume":"20","author":"E Riviere","year":"2018","unstructured":"Riviere E, Sellam J, Pascaud J, Ravaud P, Gottenberg JE, Mariette X (2018) Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis. Arthritis Res Ther 20(1):122. https:\/\/doi.org\/10.1186\/s13075-018-1628-6","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4699_CR155","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","volume":"36","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada S, Tanaka Y (2016) BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflammation and Regeneration 36(1):6. https:\/\/doi.org\/10.1186\/s41232-016-0015-4","journal-title":"Inflammation and Regeneration"},{"key":"4699_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-6-1","volume":"6","author":"JD Mellor","year":"2013","unstructured":"Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A (2013) A critical review of the role of fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 6:1\u20131. https:\/\/doi.org\/10.1186\/1756-8722-6-1","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4699_CR157","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4081\/reumatismo.2012.368","volume":"64","author":"S Canestri","year":"2012","unstructured":"Canestri S, Totaro MC, Serone E, Tolusso B, Frezza D, Gremese E, Ferraccioli G (2012) Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. Reumatismo 64(6):368\u2013373. https:\/\/doi.org\/10.4081\/reumatismo.2012.368","journal-title":"Reumatismo"},{"issue":"5","key":"4699_CR158","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.rbre.2016.09.007","volume":"57","author":"D Viecceli","year":"2017","unstructured":"Viecceli D, Garcia MP, Schneider L, Alegretti AP, Silva CK, Ribeiro AL, Brenol CV, Xavier RM (2017) Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab. Rev Bras Reumatol Engl Ed 57(5):385\u2013391. https:\/\/doi.org\/10.1016\/j.rbre.2016.09.007","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"12","key":"4699_CR159","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2009-06-229112","volume":"115","author":"C Henry","year":"2010","unstructured":"Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Remy-Martin JP, Callanan M, Traverse-Glehen A, GrandClement C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C (2010) Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood 115(12):2420\u20132429. https:\/\/doi.org\/10.1182\/blood-2009-06-229112","journal-title":"Blood"},{"issue":"9","key":"4699_CR160","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1093\/rheumatology\/kev210","volume":"54","author":"C Gamonet","year":"2015","unstructured":"Gamonet C, Deschamps M, Marion S, Herbein G, Chiocchia G, Auger I, Saas P, Ferrand C, Toussirot E (2015) The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford) 54(9):1744\u20131745. https:\/\/doi.org\/10.1093\/rheumatology\/kev210","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4699_CR161","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0966-3274(03)00059-5","volume":"12","author":"C Schroder","year":"2003","unstructured":"Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN (2003) Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 12(1):19\u201328. https:\/\/doi.org\/10.1016\/s0966-3274(03)00059-5","journal-title":"Transpl Immunol"},{"issue":"1","key":"4699_CR162","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ajg.2008.71","volume":"104","author":"SV Kane","year":"2009","unstructured":"Kane SV, Acquah LA (2009) Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 104(1):228\u2013233. https:\/\/doi.org\/10.1038\/ajg.2008.71","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"4699_CR163","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","volume":"117","author":"EF Chakravarty","year":"2011","unstructured":"Chakravarty EF, Murray ER, Kelman A, Farmer P (2011) Pregnancy outcomes after maternal exposure to rituximab. Blood 117(5):1499\u20131506. https:\/\/doi.org\/10.1182\/blood-2010-07-295444","journal-title":"Blood"},{"issue":"5","key":"4699_CR164","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10067-013-2241-3","volume":"32","author":"R Gualtierotti","year":"2013","unstructured":"Gualtierotti R, Ingegnoli F, Meroni PL (2013) Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al. Clin Rheumatol 32(5):727\u2013728. https:\/\/doi.org\/10.1007\/s10067-013-2241-3","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4699_CR165","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C Gotestam Skorpen","year":"2016","unstructured":"Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Forger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbuhl C, Ostensen M (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795\u2013810. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208840","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4699_CR166","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","volume":"55","author":"J Flint","year":"2016","unstructured":"Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, Arthanari S, Cunningham J, Flanders L, Moore L, Crossley A, Purushotham N, Desai A, Piper M, Nisar M, Khamashta M, Williams D, Gordon C, Giles I (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 55(9):1693\u20131697. https:\/\/doi.org\/10.1093\/rheumatology\/kev404","journal-title":"Rheumatology (Oxford)"},{"key":"4699_CR167","doi-asserted-by":"publisher","unstructured":"Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, Morel J, Mouthon L, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Sibilia (2008) Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 75 Suppl 1:S1\u201399. https:\/\/doi.org\/10.1016\/s1297-319x(08)73620-0","DOI":"10.1016\/s1297-319x(08)73620-0"},{"issue":"4","key":"4699_CR168","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/rheumatology\/kew493","volume":"56","author":"D De Cock","year":"2017","unstructured":"De Cock D, Birmingham L, Watson KD, Kearsley-Fleet L, Symmons DP, Hyrich KL (2017) Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. Rheumatology (Oxford) 56(4):661\u2013663. https:\/\/doi.org\/10.1093\/rheumatology\/kew493","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"4699_CR169","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10067-012-2156-4","volume":"32","author":"M Ojeda-Uribe","year":"2013","unstructured":"Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, Ternant D, Ardizzone M (2013) Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 32(5):695\u2013700. https:\/\/doi.org\/10.1007\/s10067-012-2156-4","journal-title":"Clin Rheumatol"},{"issue":"4","key":"4699_CR170","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5414\/cp203360","volume":"57","author":"SC Bae","year":"2019","unstructured":"Bae SC, Lee YH (2019) Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis. Int J Clin Pharmacol Ther 57(4):188\u2013196. https:\/\/doi.org\/10.5414\/cp203360","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"4699_CR171","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/acr.23771","volume":"71","author":"HP Tony","year":"2019","unstructured":"Tony HP, Kruger K, Cohen SB, Schulze-Koops H, Kivitz AJ, Jeka S, Vereckei E, Cen L, Kring L, Kollins D (2019) Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken) 71(1):88\u201394. https:\/\/doi.org\/10.1002\/acr.23771","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"4699_CR172","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1080\/19420862.2018.1487912","volume":"10","author":"W Park","year":"2018","unstructured":"Park W, Bozic-Majstorovic L, Milakovic D, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Molina FFC, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Garmish O, Linde T, Rekalov D, Hrycaj P, Krause A, Fomina N, Piura O, Abello-Banfi M, Suh CH, Shim SC, Lee SJ, Lee SY, Kim SH, Yoo DH (2018) Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled phase 3 trial. MAbs 10(6):934\u2013943. https:\/\/doi.org\/10.1080\/19420862.2018.1487912","journal-title":"MAbs"},{"issue":"1","key":"4699_CR173","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40259-018-00331-4","volume":"33","author":"CH Suh","year":"2019","unstructured":"Suh CH, Yoo DH, Berrocal Kasay A, Chalouhi El-Khouri E, Cons Molina FF, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Linde T, Hrycaj P, Abello-Banfi M, Hospodarskyy I, Jaworski J, Piotrowski M, Brzosko M, Krogulec M, Shevchuk S, Calvo A, Andersone D, Park W, Shim SC, Lee SJ, Lee SY (2019) Long-term efficacy and safety of biosimilar CT-P10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase III trial. BioDrugs 33(1):79\u201391. https:\/\/doi.org\/10.1007\/s40259-018-00331-4","journal-title":"BioDrugs"},{"key":"4699_CR174","doi-asserted-by":"publisher","unstructured":"Shim SC, Bozic-Majstorovic L, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Cons Molina FF, Medina-Rodriguez FG, Miranda P, Shesternya P, Chavez-Corrales J, Wiland P, Jeka S, Garmish O, Hrycaj P, Fomina N, Park W, Suh CH, Lee SJ, Lee SY, Bae YJ, Yoo DH (2019) Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized phase 3 trial. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kez152","DOI":"10.1093\/rheumatology\/kez152"},{"issue":"11","key":"4699_CR175","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/acr.23586","volume":"70","author":"SB Cohen","year":"2018","unstructured":"Cohen SB, Burgos-Vargas R, Emery P, Jin B, Cronenberger C, Vazquez-Abad MD (2018) Extension study of PF-05280586, a potential rituximab biosimilar, versus rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken) 70(11):1598\u20131606. https:\/\/doi.org\/10.1002\/acr.23586","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04699-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T15:39:21Z","timestamp":1721576361000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04699-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":175,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["4699"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04699-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"10 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}